Company Overview of Philogen S.p.A.
Philogen S.p.A., a biotechnology company, engages in the discovery, development, and production of biopharmaceuticals for the treatment of angiogenesis-related disorders. It provides Darleukin (L19-IL2), a human vascular targeting immunocytokine; Teleukin (F16-IL2), a human vascular targeting immunocytokine; Fibromun (L19-TNF), a human vascular targeting immunocytokine; RADRETUMAB (L19-I131), a human vascular targeting antibody; and Dekavil (F8-IL10), an immunocytokine consisting of a vascular targeting antibody fused to the anti-inflammatory cytokine interleukin. The company was founded in 1996 and is based in Sovicille, Italy. Philogen S.p.A. is a former subsidiary of Unknown Stake in Para...
Via Bellaria, 35
Sovicille, SI 53018
Founded in 1996
Key Executives for Philogen S.p.A.
Vice President and Director
Compensation as of Fiscal Year 2013.
Philogen S.p.A. Key Developments
Philogen S.p.A. Presents at EBD Group's 7th Annual BIO-Europe Spring Conference 2013, Mar-11-2013
Feb 7 13
Philogen S.p.A. Presents at EBD Group's 7th Annual BIO-Europe Spring Conference 2013, Mar-11-2013 . Venue: Centre Covencions International Barcelona, Plaça de Willy Brandt, 11-14, 08019 Barcelona, Spain.
Actinium Pharmaceuticals, Inc. and Philogen S.P.A. Announce Start of Pre-Clinical Development of an Alpha Therapy Based Antiangiogenesis Program
Nov 29 12
Actinium Pharmaceuticals, Inc. and Philogen S.p.A. announced that they have commenced pre-clinical development of Philogen's L19 antibody construct labeled with actinium 225 as a therapeutic payload. The L19 antibody targets newly formed blood vessels that otherwise allow cancers to grow. Clinical trials of drug candidates based on alpha emitting isotopes have so far demonstrated significant efficacy with minimal side effects in blood borne cancers, in metastases of solid cancers and in residual disease in solid cancers post-surgery. Actinium Pharmaceuticals and Philogen intend to add antiangiogenesis to this growing field of use of alpha emitters. Antiangiogenesis is a successful approach to treating numerous cancer types. Currently approved antiangiogenesis drugs act mostly by interfering with the signaling pathway used by cancer cells to stimulate growth of blood vessels. In many cases, cancer cells eventually find alternative ways to spur blood vessel growth. In contrast, Philogen's L19 targets adhesion molecules that anchor blood vessel cells which makes it less susceptible to cancer controlled pathways. Depending on the architecture of vasculature and its proximity to cancer stem cells, actinium 225 coupled with L19 could potentially offer an effective combination of properties tailor made for certain solid cancer types. The first model under consideration is glioblastoma multiforme, a difficult to treat form of brain cancer.
Philogen S.p.A. Presents at BIO-Europe 2012, Nov-12-2012
Nov 9 12
Philogen S.p.A. Presents at BIO-Europe 2012, Nov-12-2012 . Venue: CCH Congress Center Hamburg, Am Dammtor / Marseiller Str, 20355 Hamburg, Germany.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 3, 2013
September 3, 2013